Skip to main content
Fig. 3 | Cancer Cell International

Fig. 3

From: Exosomes derived from M2 type tumor-associated macrophages promote osimertinib resistance in non-small cell lung cancer through MSTRG.292666.16-miR-6836-5p-MAPK8IP3 axis

Fig. 3

Effects of M2 type TAM-derived exosomal lncRNA MSTRG.292666.16 on osimertinib resistance in non-small cell lung cancer (NSCLC) in vivo. A The level of MSTRG.292666.16 in the pCDH-lncRNA group was significantly increased compared with the control group, which suggested that H1975 cells with lncRNA MSTRG.292666.16 overexpression have been successfully established. B The changes of tumor volume with the increase of administration time. **: P < 0.01, compared with the control group; ##: P < 0.01, compared with the pCDH group. C The size of tumor in different groups after administrated with osimertinib for four weeks. D The tumor volume in different groups after four weeks of osimertinib treatment. The in vivo experiments indicated that M2 type TAM-derived exosomes and lncRNA MSTRG.292666.16 overexpression could enhance osimertinib resistance in NSCLC

Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us